推薦產品
等級
pharmaceutical primary standard
API 家族
betahistine
製造商／商標名
EDQM
應用
pharmaceutical (small molecule)
格式
neat
儲存溫度
2-8°C
InChI
1S/C8H12N2.2CH4O3S/c1-9-7-5-8-4-2-3-6-10-8;2*1-5(2,3)4/h2-4,6,9H,5,7H2,1H3;2*1H3,(H,2,3,4)
InChI 密鑰
ZBJJDYGJCNTNTH-UHFFFAOYSA-N
一般說明
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
應用
Betahistine mesilate EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
包裝
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
其他說明
Sales restrictions may apply.
相關產品
產品號碼
描述
訂價
儲存類別代碼
11 - Combustible Solids
水污染物質分類（WGK）
WGK 3
閃點（°F）
Not applicable
閃點（°C）
Not applicable
Isilay Oz et al.
ORL; journal for oto-rhino-laryngology and its related specialties, 75(4), 211-220 (2013-08-01)
The aim of this study was to evaluate the effect of combined hearing and tinnitus masking devices that are appropriately programmed for acoustic stimulations using wide-band noise over the specific frequency range of tinnitus. A total of 21 patients were
Looks vestibular: irrational prescribing of antivertiginous drugs for older dizzy patients in general practice.
Otto R Maarsingh et al.
The British journal of general practice : the journal of the Royal College of General Practitioners, 62(603), 518-520 (2012-12-26)
Adriana Pontin Garcia et al.
Brazilian journal of otorhinolaryngology, 79(3), 366-374 (2013-06-08)
Virtual reality technology can provide a wide range of sensory stimuli to generate conflicts of varying degrees of complexity in a safe environment. To verify the effect of a virtual realitybased balance rehabilitation program for patients with Menière's disease. This
R Gürkov et al.
European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 270(4), 1231-1235 (2012-07-05)
This study aimed to assess whether standard-dose Betahistine (48 mg daily) exerts an effect upon the degree of endolymphatic hydrops in patients with Menière's disease using a retrospective case series in the setting of a tertiary neurotology referral centre. In
Fritz Ihler et al.
PloS one, 7(6), e39086-e39086 (2012-06-30)
Betahistine is a histamine H(1)-receptor agonist and H(3)-receptor antagonist that is administered to treat Menière's disease. Despite widespread use, its pharmacological mode of action has not been entirely elucidated. This study investigated the effect of betahistine on guinea pigs at
我們的科學家團隊在所有研究領域都有豐富的經驗，包括生命科學、材料科學、化學合成、色譜、分析等.
聯絡技術服務